<DOC>
	<DOCNO>NCT00250354</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness oral risperidone ( antipsychotic medication ) treatment conduct disorder disruptive behavior disorder child age 5 12 mild , moderate , borderline mental retardation .</brief_summary>
	<brief_title>A Study Safety Effectiveness Risperidone Treatment Conduct Disorder Other Disruptive Behavior Disorders Children Ages 5 12 With Mild , Moderate , Borderline Mental Retardation</brief_title>
	<detailed_description>Conduct psychiatric disorder find among high proportion people mental retardation among people mentally retarded . Among many different treatment approach conduct disorder drug therapy , behavioral treatment , psychotherapy , cognitive social learning . Studies suggest neuroleptic drug , risperidone , may beneficial treat conduct disorder mental retardation . This randomized , double-blind study evaluate effectiveness risperidone compare placebo treatment child 5 12 year age mild , moderate , borderline mental retardation display destructive behavior . The study 2 phase : run-in phase 1 week treatment phase 6 week . Patients receive placebo take orally day first week ( run-in ) . On basis score Nisonger Child Behavior Rating Form ( N-CBRF ) first week , patient either continue double-blind treatment phase discontinue study . During treatment phase patient receive risperidone oral solution daily start dose 0.01 mg/kg body weight , increase gradually investigator 's discretion 0.06 mg/kg ( maximum ) , placebo 6 week . A parent caregiver evaluate child 's behavior symptom schedule office visit course treatment . The primary measure efficacy change baseline end treatment Conduct Problem subscale N-CBRF . Other efficacy assessment include change Aberrant Behavior Checklist ( ABC ) , Behavioral Problems Inventory ( BPI ) , Clinical Global Impression ( CGI ) , rating system use evaluate overall severity clinical change . Safety assessment include incidence adverse event throughout study ; weekly measurement vital sign ( pulse , temperature , blood pressure ) evaluation presence severity extrapyramidal symptom Extrapyramidal Symptom Rating Scale ( ESRS ) ; clinical laboratory test ( hematology , biochemistry , urinalysis ) study initiation end treatment . The study hypothesis risperidone well tolerated effective treatment conduct disorder child age 5 12 year mild , moderate , borderline mental retardation . Risperidone oral solution 1.0 mg/mL daily . Days 1 2 dose 0.01 mg/kg body weight , Day 3 dose 0.02 mg/kg , increase gradually 0.06 mg/kg ( maximum ) daily 6 week . Dose may increase decreased investigator 's discretion</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Problem Behavior</mesh_term>
	<mesh_term>Conduct Disorder</mesh_term>
	<mesh_term>Attention Deficit Disruptive Behavior Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Meets Axis I diagnosis criterion Conduct Disorder Oppositional Defiant Disorder Disruptive Behavior Disorder otherwise specify ( DSMIV , Diagnostic Statistical Manual Mental Diseases , 4th edition ) total rating &gt; =24 Nisonger Child Behavior Rating Form ( NCBRF ) Conduct Problem Subscale . ( Patients conduct disorder also meet DSMIV criterion Attention Deficit/Hyperactivity Disorder ( AD/HD ) eligible . ) meet DSMIV Axis II diagnosis criterion Mild Mental Retardation , Moderate Mental Retardation Borderline Intellectual Functioning ( diagnose represent intelligence quotient [ IQs ] range 35 84 ) DSMIV diagnosis Pervasive Development Disorder , Schizophrenia , Other Psychotic Disorders head injury cause mental impairment seizure disorder currently require medication history tardive dyskinesia ( condition uncontrollable movement tongue , lip , face , trunk , hand foot see patient receive longterm medication certain type antipsychotic drug ) neuroleptic malignant syndrome ( rare psychotropicdrug reaction , may characterize confusion , reduce consciousness , high fever pronounce muscle stiffness ) know hypersensitivity , intolerance , unresponsiveness risperidone .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>conduct disorder</keyword>
	<keyword>oppositional deficit disorder</keyword>
	<keyword>disruptive behavior disorder otherwise specify</keyword>
	<keyword>ADHD</keyword>
	<keyword>risperidone</keyword>
	<keyword>antipsychotropic agent</keyword>
	<keyword>child</keyword>
</DOC>